As marijuana use becomes more prevalent, a severe illness linked to frequent cannabis use is also on the rise. Cannabinoid (or Cannabis) hyperemesis syndrome, also known as CHS, is an often ...
Positive Phase 2b Results from the CAN-002 Study of PP-01, an investigational product intended to mitigate Cannabis Withdrawal Syndrome in patients with Cannabis Use Disorder PHOENIXVILLE, Pa., June ...
CAN-002 was a randomized, double-blind, placebo-controlled study with 234 participants between ages 18-55, seeking to discontinue cannabis, at 22 US addiction centers. Participants in the study ...
Cannabis use disorder (CUD), also known as marijuana use disorder, is defined by compulsive use of cannabis despite adverse consequences, difficulty controlling use, and withdrawal symptoms. The ...
Chronic cannabis users suffering from cannabis hyperemesis syndrome can now be formally diagnosed. Why it matters: The World Health Organization's recent move to formally name the condition — which ...
PHOENIXVILLE, Pa., April 16, 2025 /PRNewswire/ -- PleoPharma, Inc. ("PleoPharma" or the "Company"), a privately held company focused on Cannabis-related health issues, announced today that the U.S.
January 31, 2008 — Cannabis withdrawal is clinically important and warrants inclusion in the Diagnostic and Statistical Manual (DSM), researchers argue in an article in the January 1 issue of Drug and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results